menu
    • menu

    Company profile for Cullgen

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    To utilize our revolutionary and proprietary targeted protein degradation technology to create, in a highly efficient manner, new drugs for treatment of diseases that currently lack effective therapies. Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. We are developing our pro...
    To utilize our revolutionary and proprietary targeted protein degradation technology to create, in a highly efficient manner, new drugs for treatment of diseases that currently lack effective therapies. Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. We are developing our proprietary technology platform, uSMITE™, based on recent advances in the science of protein degradation. Typically, drugs are designed to interact with the functional sites of proteins and block their activities.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CullgenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12671 High Bluff Drive - Suite 130, San Diego, California 92130
    Telephone
    Telephone
    +1 -858-284-0115
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cullgen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cullgen's CG001419 Shows Positive Phase 1 Results
    Cullgen's CG001419 Shows Positive Phase 1 Results

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204662/0/en/Cullgen-Reports-Positive-Results-from-Phase-1-Study-of-its-Novel-Non-Opioid-Product-Candidate-CG001419-for-Pain.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Cullgen Wraps Phase 1 Trial Enrollment for Non-Opioid Pain Drug
    Cullgen Wraps Phase 1 Trial Enrollment for Non-Opioid Pain Drug

    18 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/18/3152268/0/en/Cullgen-Completes-Enrollment-in-Phase-1-Trial-of-its-Novel-Non-Opioid-Pain-Product-Candidate-CG001419.html

    GLOBENEWSWIRE
    18 Sep 2025
    Share Share
    Cullgen Begins Phase I For Oral Pan-TRK Degrader In Pain Treatment
    Cullgen Begins Phase I For Oral Pan-TRK Degrader In Pain Treatment

    22 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/22/3013421/0/en/Cullgen-Begins-Phase-1-Dosing-of-its-Potential-First-in-Class-Oral-Pan-TRK-Protein-Degrader-for-Acute-and-Chronic-Pain.html

    GLOBENEWSWIRE
    22 Jan 2025
    Share Share
    Pulmatrix & Cullgen Announce Proposed Merger
    Pulmatrix & Cullgen Announce Proposed Merger

    13 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pulmatrix-and-cullgen-announce-proposed-merger-302303818.html

    PR NEWSWIRE
    13 Nov 2024
    Share Share
    Cullgen Announces Additions to Board of Directors and Scientific Advisory Board
    Cullgen Announces Additions to Board of Directors and Scientific Advisory Board

    16 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240116086836/en

    BUSINESSWIRE
    16 Jan 2024
    Share Share
    Astellas pays Cullgen $35M upfront to form protein degrader pact
    Astellas pays Cullgen $35M upfront to form protein degrader pact

    16 Jun 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/astellas-adds-cullgen-parade-protein-degrader-pacts-paying-35m-upfront-access-tech

    Nick Paul Taylor FIERCE BIOTECH
    16 Jun 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search